Full-Time

Executive Director

Toxicology

Confirmed live in the last 24 hours

Neurocrine Biosciences

Neurocrine Biosciences

1,001-5,000 employees

Biotechnology
Healthcare

Compensation Overview

$265.4k - $384.3kAnnually

+ Bonus + Equity Incentive Program

Expert

San Diego, CA, USA

Category
Bioinformatics
Computational Biology
Genomics
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • PhD in Toxicology, Pathology or closely related discipline and 12+ years of pharmaceutical/biotech experience, including managing clinical Contract Research Organizations. Experience in toxicologic pathology is beneficial OR D.V.M and 8+ years of similar experience noted above
  • Extensive previous leadership experiences also required
  • Acts as a 'trusted advisor' across the company and may be recognized as an external expert
  • Provides strategy, vision and direction regarding issues that may have company-wide impact
  • Requires in-depth knowledge of the functional area, business strategies, and the company’s goals
  • Possesses industry-leading knowledge of Toxicology assessment of small molecules and biologics
  • Must be self-motivated, detail-oriented, decisive
  • Ability to quickly learn and think independently
  • Excellent interpersonal & communication skills with the ability to interact professionally and effectively with peers, management, and leadership both within and outside the Company
  • Excellent managerial skills and experience fostering career development of direct and indirect reports
  • Demonstrated ability to influence and lead others
  • Extensive knowledge of toxicologic pathology is beneficial
  • Extensive knowledge of managing clinical Contract Research Organizations (CRO's)
  • Demonstrated involvement in the preparation of INDs, CTAs, NDAs, and MAAs
  • Maintains broad knowledge of scientific principles and theories and possesses intellectual mastery of multiple scientific areas
Responsibilities
  • Provides leadership, mentorship, and oversight to the Toxicology function in their conduct of all nonclinical safety assessments for Neurocrine’s discovery and development compounds
  • Drives the strategic vision and direction of the Toxicology function at Neurocrine to enable development of world-class capabilities in support of numerous small molecule and biologic modalities
  • Works in collaboration with other Research and Development Team members and with Neurocrine leadership to ensure safety pharmacology and toxicology support is provided to ensure provision of requisite data in a timely manner to meet development goals
  • Critically evaluate toxicology results and provides timely strategic advice to project teams and senior management on the potential impact of toxicology results on Program and Clinical/Regulatory strategy
  • Oversee and provide direction in the preparation of Safety Pharmacology and Toxicology sections of regulatory documents (IND, CTA, NDA, briefing books, Investigator Brochures, etc.)
  • Represent Preclinical Development on discovery and development-stage program teams
  • Develops critical insights from data summaries and shapes presentations of results to peers, colleagues and Neurocrine Management
  • Oversees the adherence to all SOPs for Toxicology
  • Proactively research and stay current on all applicable regulatory guidances
  • Other duties as assigned
Desired Qualifications
  • Extensive knowledge of toxicologic pathology is beneficial
  • Extensive knowledge of managing clinical Contract Research Organizations (CRO's)
Neurocrine Biosciences

Neurocrine Biosciences

View

Company Stage

IPO

Total Funding

N/A

Headquarters

San Diego, California

Founded

1992

Simplify Jobs

Simplify's Take

What believers are saying

  • CRENESSITY's FDA approval marks a significant advancement in CAH treatment.
  • Collaboration with Nxera Pharma strengthens Neurocrine's position in neuropsychiatric therapeutics.
  • Participation in major healthcare conferences boosts Neurocrine's visibility and investor relations.

What critics are saying

  • Increased competition in muscarinic agonist market may impact Neurocrine's market share.
  • Reliance on PANTHERx Rare for distribution poses potential partnership risks.
  • High cost of CRENESSITY could limit patient accessibility and market penetration.

What makes Neurocrine Biosciences unique

  • CRENESSITY is the first non-steroidal treatment for classic congenital adrenal hyperplasia.
  • Neurocrine's muscarinic agonist portfolio targets innovative treatments for neuropsychiatric disorders.
  • Partnership with Pantherx® Rare enhances patient access to rare disease treatments.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Parental Leave

Health Insurance

Dental Insurance

Vision Insurance

Paid Holidays